LY3848575 + Placebo
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuropathic Pain
Conditions
Neuropathic Pain, Distal Sensory Polyneuropathy
Trial Timeline
Aug 22, 2024 → Sep 1, 2026
NCT ID
NCT06568042About LY3848575 + Placebo
LY3848575 + Placebo is a phase 2 stage product being developed by Eli Lilly for Neuropathic Pain. The current trial status is active. This product is registered under clinical trial identifier NCT06568042. Target conditions include Neuropathic Pain, Distal Sensory Polyneuropathy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06568042 | Phase 2 | Active |
Competing Products
20 competing products in Neuropathic Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CHF6467 active | Comac Medical | Phase 1/2 | 33 |
| LY3857210 + Placebo | Eli Lilly | Phase 2 | 52 |
| OK-101 0.05% + OK-101 0.1% + Placebo | OKYO Pharma | Phase 2 | 44 |
| YHD1119 + Lyrica | Yuhan | Phase 3 | 77 |
| YHD1119 300mg + YHD1119 300mg | Yuhan | Phase 1 | 33 |
| pregabalin sustained release tablet + pregabalin immediate release capsule | Yuhan | Approved | 85 |
| DS-5565 + placebo | Daiichi Sankyo | Phase 3 | 77 |
| Mirogabalin + Placebo | Daiichi Sankyo | Phase 3 | 77 |
| DS-1971a + placebo + pregabalin | Daiichi Sankyo | Phase 2 | 52 |
| DS-5565 | Daiichi Sankyo | Phase 3 | 77 |
| Placebo + Mirogabalin | Daiichi Sankyo | Phase 3 | 77 |
| Qutenza | Astellas Pharma | Pre-clinical | 23 |
| Qutenza exposure | Astellas Pharma | Pre-clinical | 23 |
| Duloxetine + Pregabalin + Placebo | Shionogi | Approved | 85 |
| LY3016859 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4065967 + Placebo | Eli Lilly | Phase 2 | 52 |
| ABT-639 + pregabalin + Placebo | AbbVie | Phase 2 | 52 |
| onabotulinum toxin A | AbbVie | Phase 2 | 52 |